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One of the main mechanisms responsible for MDS
molecular pathogenesis involves the activation of tyro-
sine-kinase receptors, sucha sF L T 3 ,R A Sp r o t e i n s ,a n d
deregulation of apoptotic pathways. Regarding this, new
drugs have been developed to target pathways involved
in malignancy, such as Farnesyltransferase Inhibitors
(IFTs) and proteasome inhibitors (PI). This work aims
to clarify the role of IFTs and PI as potential therapeutic
agents in Myelodysplastic Syndrome (MDS).
For this, F-36P cells, were incubated with different
concentrations of a-HFPA (IFT) and MG262 (PI), as
single agents and in association with the conventional
therapeutic drug, Cytosine Arabinoside (Ara-C). Cell
growth and viability was evaluated by Trypan Blue test.
Cell death was analyzed by optic microscopy and flow
cytometry (FC). Expression of proteins involved in apop-
tosis and cell cycle regulation was evaluated by FC. The
detection of RAS and FLT3 mutations was accessed by
sequentiation and PCR, respectively.
Our results show that a-HFPA and MG262, in mono-
therapy, induce a decrease in cell growth and viability in
a time and dose-dependent manner (IC50, a-HFPA 125
μM; MG262 100 nM). The antiproliferative effect of
a-HFPA could be related to RAS/MAPK pathway inhi-
bition, as we observed a decrease in cyclin D1 levels,
while the cytotoxicity induced by MG262 to an increase
in BAX expression. Our results show that a-HFPA is
effective independently of RAS mutations, once we
didn’t identify mutations in none of the isoforms stu-
died, but we observe ITD mutations in FLT3 gene.
These results suggest that IFTs and PIs may constitute a
potential therapeutic approach as single agents in MDS.
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